Kingsley Capital Partners

QuantifiedESG is a company that specializes in developing assessment and rating tools focused on environmental, social, and governance (ESG) evaluations. Its platform quantitatively analyzes various social and environmental risk factors, producing detailed ESG evaluation reports. These reports assess the management of business and asset risks, allowing clients to evaluate the sustainability of their supply chains. By providing objective insights into ESG performance, QuantifiedESG supports businesses in making informed decisions regarding sustainable practices and risk management.

Spring Fibre is a London-based operator of fiber optics networks that specializes in providing wholesale fiber network solutions. The company focuses on developing robust infrastructure to facilitate high-speed internet access, particularly in underpenetrated and hard-to-reach areas. By enabling retailers to offer reliable broadband services, Spring Fibre aims to enhance connectivity and meet the growing demand for efficient internet solutions.

Atlas Tower Group is a wireless infrastructure solution provider focused on designing and constructing 5G-ready towers and rooftops. The company specializes in acquiring telecommunication sites and offers comprehensive installation and integration services for active infrastructure. By addressing the needs of multiple tenants, Atlas Tower Group enables mobile network operators to meet the increasing demand for coverage and capacity, thereby enhancing connectivity in various regions.

Equinox International is a cannabis company that specializes in the development of pharmaceutical quality products. It operates as a vertically integrated land-to-brand entity, focusing on a diverse array of medical cannabis offerings. The company provides a wide selection of products including cannabis oil, tinctures, tonics, tablets, capsules, and topical creams and lotions. This product range is designed to meet various therapeutic needs and personal preferences, ensuring that clients can find suitable options for specific indications and lifestyles.

Oxford Cannabinoid Technologies Ltd. is a biopharmaceutical company based in Oxford, United Kingdom, dedicated to the research and development of cannabinoid-based compounds and therapies. Established in 2017, the company aims to address various medical conditions, including inflammatory diseases, oncology, neurological disorders, and pain management. It employs a drug development approach that incorporates proprietary cannabinoid derivatives, natural phytocannabinoids, and in-licensed compounds. The company's primary focus is on the pain market, with plans to develop a portfolio of drug candidates intended for regulatory approval as licensed pain medications, all while collaborating with leading medical researchers to meet high unmet medical needs.